Literature DB >> 10511397

Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria.

J Heritage1, F H M'Zali, D Gascoyne-Binzi, P M Hawkey.   

Abstract

Resistance to beta-lactam antibiotics has been a problem for as long as these drugs have been used in clinical practice. In clinically significant bacteria the most important mechanism of resistance is the production of one or more beta-lactamases, enzymes that hydrolyse the beta-lactam bond characteristic of this family of antibiotics. Prominent among the beta-lactamases produced by the Enterobacteriaceae is the SHV family. The first reported SHV beta-lactamase had a narrow spectrum of activity. By the accumulation of point mutations at sites that affect the active site of the enzyme, a family of derivatives of SHV-1 has evolved. Derivatives of SHV-1 either have an extended spectrum of activity, capable of inactivating third-generation cephalosporins, or are resistant to beta-lactamase inhibitors. This review describes the evolution and spread of the SHV family of beta-lactamases, introducing the structure-function analysis made possible by DNA sequence analysis. It also reviews the methods used to characterize members of this family of beta-lactamases, indicating some of the difficulties involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511397     DOI: 10.1093/jac/44.3.309

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae.

Authors:  L Poirel; I Le Thomas; T Naas; A Karim; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group.

Authors:  C De Champs; D Sirot; C Chanal; R Bonnet; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

4.  Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.

Authors:  Sergei Vakulenko; Dasantila Golemi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Discrimination of SHV beta-lactamase genes by restriction site insertion-PCR.

Authors:  A Chanawong; F H M'Zali; J Heritage; A Lulitanond; P M Hawkey
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Molecular characterization of a novel plasmid-encoded cefotaximase (CTX-M-12) found in clinical Klebsiella pneumoniae isolates from Kenya.

Authors:  S Kariuki; J E Corkill; G Revathi; R Musoke; C A Hart
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem.

Authors:  Laurent Poirel; Claire Héritier; Isabelle Podglajen; Wladimir Sougakoff; Laurent Gutmann; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 8.  Molecular epidemiology of clinically significant antibiotic resistance genes.

Authors:  P M Hawkey
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

9.  OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.

Authors:  Paul G Higgins; Laurent Poirel; Marlene Lehmann; Patrice Nordmann; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

10.  Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis.

Authors:  Soichiro Kimura; Masaji Ishiguro; Yoshikazu Ishii; Jimena Alba; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.